Related Experiment Video
Updated: Apr 11, 2026

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
Do we have to anticoagulate patients with cerebral venous thrombosis?
Gergely Feher1, Zsolt Illes, David Hargroves
1Szigetvar Hospital, Szigetvár, Hungary - feher.gergely@pt.
Insights
Anticoagulation for cerebral venous thrombosis (CVT) shows a low recurrence rate, but its long-term benefits remain unclear. Further randomized trials are needed to fully elucidate the role of anticoagulation in CVT management.
Area of Science:
- Neurology
- Hematology
- Vascular Medicine
Background:
- Cerebral venous thrombosis (CVT) is a rare but serious form of venous thromboembolism.
- Anticoagulation is standard treatment, yet its long-term efficacy requires further investigation.
Purpose of the Study:
- To review literature on anticoagulation benefits in CVT.
- To analyze follow-up data on CVT recurrence and thrombotic events.
Main Methods:
- Literature-based review of 15 follow-up studies.
- Analysis of data from 2422 patients with a mean follow-up of 37.9 months.
Main Results:
- Overall mortality was 6.5%, with 76.4% achieving a favorable outcome.
- Recurrent CVT occurred in 3.7% and other thrombotic events in 5.4% of patients.
- Initial and long-term anticoagulation was administered to 85.5% and 82.1% of patients, respectively.
Conclusions:
- Current studies provide inconclusive results on the clinical impact of anticoagulation in CVT.
- Low recurrence rates suggest a need for clarification through randomized controlled trials.
Abstract:
Cerebral venous thrombosis (CVT) is a rare form of venous thromboembolism (VTE). Although anticoagulation is recommended for the initial and long term treatment with regards to thrombotic risks for patients with CVT, the role of anticogalution has not been fully elucidated. The aim of our literature based review was collect articles showing the benefit of anticoagulation in CVT and gathering the data of follow-up studies focusing on the recurrence of CVT and other thrombotic events. We have identified 15 follow-up studies studies with 2422 patients. The mean duration of follow-up was 37.9 months. Death occured in 6.5% and 76.4% of the patients had favorable outcome; 85.5% received initial anticoagulation with ultrafractionated or low molecular weight heparin and 82.1% received long-term anticoagulation. Recurent CVT occured in 3.7% and other thrombotic event occured in 5.4%. The mentioned studies have led to incoclusive results with regards to the clinical outcome and the presence or absence of anticoagulation. The role of long term anticoagulation should be clarified in randomized multicentre studies as the recurrence rate seems to be low and the outcome of a second event as good as that of the first one irrespective of underlying risk factors.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
